Cargando…
New emerging targets in cancer immunotherapy: the role of VISTA
The immune surveillance system is complex and regulated by different actors. Programmed death protein-ligand 1 (PD-L1), the only approved biomarker in clinical practice, has proven to be imperfect in selecting patients to immune checkpoint inhibitors treatment. Therefore, new biomarkers, and new the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305420/ https://www.ncbi.nlm.nih.gov/pubmed/32554470 http://dx.doi.org/10.1136/esmoopen-2020-000683 |
_version_ | 1783548457483501568 |
---|---|
author | Tagliamento, Marco Bironzo, Paolo Novello, Silvia |
author_facet | Tagliamento, Marco Bironzo, Paolo Novello, Silvia |
author_sort | Tagliamento, Marco |
collection | PubMed |
description | The immune surveillance system is complex and regulated by different actors. Programmed death protein-ligand 1 (PD-L1), the only approved biomarker in clinical practice, has proven to be imperfect in selecting patients to immune checkpoint inhibitors treatment. Therefore, new biomarkers, and new therapeutic targets, are needed to maximise the efficacy of immunotherapy. V-domain Ig Suppressor of T-cell Activation (VISTA) is a programmed death protein-1 (PD-1) homolog expressed on T cells and on antigen-presenting cells, which regulates processes of activation and repression of the immune system with not yet completely clarified mechanisms. Its blockage has demonstrated in vitro and in vivo antitumour activity. The clinical research of VISTA antagonists is ongoing. Particularly, CA-170, an orally delivered dual inhibitor of VISTA and PD-L1, has shown to have clinical efficacy in phase I and II clinical trials in different advanced solid tumour types. Further data are needed to define whether this drug class can become a new therapeutic option for patients with VISTA expressing cancers. |
format | Online Article Text |
id | pubmed-7305420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73054202020-06-22 New emerging targets in cancer immunotherapy: the role of VISTA Tagliamento, Marco Bironzo, Paolo Novello, Silvia ESMO Open Review The immune surveillance system is complex and regulated by different actors. Programmed death protein-ligand 1 (PD-L1), the only approved biomarker in clinical practice, has proven to be imperfect in selecting patients to immune checkpoint inhibitors treatment. Therefore, new biomarkers, and new therapeutic targets, are needed to maximise the efficacy of immunotherapy. V-domain Ig Suppressor of T-cell Activation (VISTA) is a programmed death protein-1 (PD-1) homolog expressed on T cells and on antigen-presenting cells, which regulates processes of activation and repression of the immune system with not yet completely clarified mechanisms. Its blockage has demonstrated in vitro and in vivo antitumour activity. The clinical research of VISTA antagonists is ongoing. Particularly, CA-170, an orally delivered dual inhibitor of VISTA and PD-L1, has shown to have clinical efficacy in phase I and II clinical trials in different advanced solid tumour types. Further data are needed to define whether this drug class can become a new therapeutic option for patients with VISTA expressing cancers. BMJ Publishing Group 2020-06-18 /pmc/articles/PMC7305420/ /pubmed/32554470 http://dx.doi.org/10.1136/esmoopen-2020-000683 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Tagliamento, Marco Bironzo, Paolo Novello, Silvia New emerging targets in cancer immunotherapy: the role of VISTA |
title | New emerging targets in cancer immunotherapy: the role of VISTA |
title_full | New emerging targets in cancer immunotherapy: the role of VISTA |
title_fullStr | New emerging targets in cancer immunotherapy: the role of VISTA |
title_full_unstemmed | New emerging targets in cancer immunotherapy: the role of VISTA |
title_short | New emerging targets in cancer immunotherapy: the role of VISTA |
title_sort | new emerging targets in cancer immunotherapy: the role of vista |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305420/ https://www.ncbi.nlm.nih.gov/pubmed/32554470 http://dx.doi.org/10.1136/esmoopen-2020-000683 |
work_keys_str_mv | AT tagliamentomarco newemergingtargetsincancerimmunotherapytheroleofvista AT bironzopaolo newemergingtargetsincancerimmunotherapytheroleofvista AT novellosilvia newemergingtargetsincancerimmunotherapytheroleofvista |